Mesna (sodium 2-mercaptoethane sulfonate) is an adjuvant used in cancer chemotherapy involving cyclophosphamide and ifosfamide. It is currently marketed by Baxter as Uromitexan®. Cyclophosphamide is a nitrogen mustard alkylating agent, used to treat various types of cancer and some autoimmune disorders. ... Baxter refers to more than one place. ...
Mesna is used therapeutically to reduce the incidence of haemorrhagic cystitis and haematuria when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy. These two anticancer agents, in vivo, may be converted to urotoxic metabolites such as acrolein. Mesna assists to neutralise these metabolites by binding through its sulfhydryl-moieties, and also increases urinary excretion of cysteine. In medicine, hematuria is the presence of blood in the urine. ... Acrolein is a severe pulmonary irritant and lacrimating agent, historically it has been used as a chemical weapon during World War I. Acrolein is described as having a piercing, disagreeable, acrid odor. ... In organic chemistry, a sulfhydryl group or thiol group is a functional group composed of a sulfur and a hydrogen atom (-SH). ... Cysteine is a naturally occurring hydrophobic amino acid which has a sulfhydryl group and is found in most proteins, however only in small quantities. ...
This article is a stub. You can help by adding to it (http://en.wikipedia.org/w/index.php?title=Mesna&action=edit).
Mesna is a medicine that helps protect the inside lining of the bladder from damage due to certain chemotherapy drugs.
Mesna is a medicine that is approved by the Food and Drug Administration (FDA) for use in combination with the chemotherapy drug ifosfamide to protect the bladder lining from irritation due to the chemotherapy.
Mesna should prevent most bleeding from the bladder, however patients may be asked to check their urine for traces of blood with a chemical strip that is dipped into the urine sample.
Because mesna is used in combination with ifosfamide, it is difficult to distinguish the adverse reactions which may be due to mesna from those caused by the concomitantly administered cytotoxic agent.
IV-oral-oral: Mesna is given as an IV bolus injection in a dosage equal to 20 percent of the ifosfamide dosage at the time of ifosfamide administration.
Mesna tablets are given orally in a dosage equal to 40 percent of the ifosfamide dose at 2 and 6 hours after each dose of ifosfamide.
Share your thoughts, questions and commentary here
Want to know more? Search encyclopedia, statistics and forums:
Press Releases |
The Wikipedia article included on this page is licensed under the
Images may be subject to relevant owners' copyright.
All other elements are (c) copyright NationMaster.com 2003-5. All Rights Reserved.
Usage implies agreement with terms, 1022, m